Sanhe, China
Sanhe, China

Time filter

Source Type

This invention involves a method for preparing high-contentconjugated linoleic acid (CLA) products with common vegetable oil. This invention includes alcoholysis, purification and isomerization of vegetable oil. Alcoholysis is for preparing correspondingmethyl ester or ethyl ester with glyceride; purification of methyl ester or ethyl ester is for obtaining methyl linoleate or ethyl linoleate of content over 85% through silver-basedsilicagel columnchromatography; high-content CLA is obtained after alkali-catalyzed conjugation of methyl linoleate or ethyl linoleate, and CLA products are prepared as needed. This invention changes the status quo of preparing high-content CLA with safflower oil alone, expands sources of CLA, and develops an efficient technology for separation and purification of linoleic acid. The CLA obtained is of high purity and meets applications in pharmaceutical, health care products and other industries.


The present invention provides a composition for improving macular pigment optical density and preventing or treating age-related macular optical degeneration. The composition comprises lutein, zeaxanthin and tea extracts, wherein the weight ratio of zeaxanthin to lutein is more than or equal to 1. The composition may prevent formation of choroidal neovascularization to achieve effects on comprehensively preventing or treating age-related macular optical degeneration (AMD).


The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K X-ray diffraction spectrum, has a strong peak at a diffraction angle 2 being 18.9 DEG , and has a very strong absorption peak at a diffraction angle 2 being 22.8 DEG. The reduction type coenzyme Q10 powder is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability.


Provided is a separation and purification method for vancomycin hydrochloride of high purity. The method comprises the following steps: (1) obtaining a vancomycin hydrochloride solution from a crude vancomycin product by ion exchange chromatography and obtaining a concentrate by nanofiltration desalination and concentration; (2) adjusting the concentrate with a hydrochloric acid solution and then performing a column chromatography using a reverse chromatography column for the adjusted concentrate; (3) collecting the chromatographic solution of vancomycin to obtain a mixed chromatographic solution; (4) adjusting the mixed chromatographic solution, and separating the solution and the salts by nanofiltration desalination and concentration to obtain a concentrate; and (5) obtaining a vancomycin dry powder with a chromatographic purity of up to 99% and a pure white appearance by dehydrating and drying the concentrate of step (4), or by solvent crystallization or salting-out crystallization.


Patent
Zhejiang Medicine Co., Shanghai Health Creation Center for Biopharmaceutical R & D Co. and Shanghai Institute of Pharmaceutical Industry | Date: 2015-11-04

The present invention provides a glycopeptide compound or pharmaceutically acceptable salt thereof as shown in Formula (I) or (II), and a method for preparing same, and pharmaceutical compositions and applications thereof, wherein the definition of R_(1), R_(2), R_(3), R_(4), R_(5) is the same as that of the specification. The glycopeptide compound of the present invention has in-vitro antibacterial activity and has important significance for development of new antibacterial agents.


Patent
ZheJiang Medicine Co. | Date: 2015-05-20

The invention discloses a method for preparing high-content zeaxanthin. In the conventional preparation methods, some methods adopt certain toxic organic solvents; some methods require the multi-step crystallization process; and some methods are featured by long reaction time, high temperature and lower product yield, thus being not suitable for industrial production. The invention adopts lutein crystal or its fatty acid ester as the raw material and utilizes isomerization reaction to produce zeaxanthin, and is characterized in that a mixed catalyst consisting of an organic base catalyst and a cocatalyst is used in the isomerization reaction, wherein the cocatalyst is palladium carbon. The invention has the advantages of simple process route, low reaction temperature, short reaction time, good product purity and high yield, thus being suitable for industrial production, and no poisonous and harmful organic solvent residues in the product, thus being suitable for the use as a food additive or drug.


Patent
ZheJiang Medicine Co. | Date: 2016-11-23

Provided are a linezolid intermediate and the preparation method thereof and a method for synthesizing linezolid. The structure of the intermediate is shown as formula F2, wherein the compound is prepared by a condensation reaction of (S)-N-(3-chloro-2-hydroxy-1-propyl) acetamide and the compound shown in formula F4. In the preparation methods of the compound shown in formula F2 and linezolid, the reaction system is mild, side reactions are few and the product yield is high.


The present invention provides a high-content carotenoid compound from adonis amurensis. The content of the total carotenoid of the carotenoid compound is higher than 95%. The content of all-trans (3S, 3S)-carotenoid is higher than 80%. The carotenoid crystals have a high purity, and can be used in multiple forms in the fields of a dietary supplement of a human being, a food additive, a feed additive and a cosmetic product. In addition, the present invention also provides a method for manufacturing the compound.


Patent
Zhejiang Medicine Co. and Shanghai Institute of Pharmaceutical Industry | Date: 2016-07-20

The present invention provides a method for preparing an intermediate compound of sitagliptin represented by formula I. The preparation method comprises: dissolving a compound represented by formula II into an organic solvent; and under the catalysis of fatty acid and effect of chlorosilane, performing a reduction reaction of carbon-carbon double bonds, so as to obtain the intermediate compound of sitagliptin represented by formula I, R being methyl or formoxyl. Te preparation method of the present invention avoids precious metal as a catalyst, and accordingly, the cost is low, the post-treatment is simple, the product has a high yield, chemical purity and optical purity, and de% is greater than 99.6%, and the preparation method can be used in synthesis of sitagliptin and is suitable for industrial production.


The present invention provides a a 2, 6-di-nitrogen-containing substituted purine derivative having a formula (I) structure, or pharmaceutical salt or hydrate thereof, and preparation method and use thereof. The compound is broad spectrum anticancer, low toxicity, high anticancer activity and good stability.

Loading Zhejiang Medicine Co. collaborators
Loading Zhejiang Medicine Co. collaborators